الجزارا فارسی
روایت خاورمیانه 
Since legal changes in 2018, access to medical cannabis in the UK has become easier. These changes, made by the then government, allow the NHS and private providers to prescribe cannabis-based medicinal products. But the question is whether these reforms have truly benefited patients or only served private companies.
The role of the NHS and private services
Currently, the NHS only prescribes cannabis for a few specific conditions such as rare and severe forms of epilepsy and muscle spasms caused by MS. However, statistics show that the vast majority of prescriptions are made through private health services. This has led patients, especially those seeking unconventional treatments, to gravitate towards these types of services.
Despite the potential benefits of cannabis medications, there are also concerns about the quality and price of these products. Patients often have to pay high costs to obtain these medications, which poses a challenge for many of them. Do these facts indicate a profitable market for private companies?
Patient experiences
In light of these changes, many patients in the UK have shared their experiences with medical cannabis. Some speak of the positive impact these medications have had on their quality of life, while others complain about issues such as difficult access and high costs.
Now the question arises: Are we witnessing a real revolution in medical treatments or just a new wave of commercialization of drugs? Are patients truly gaining their rights in this process, or are they becoming tools for profit?
